Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin completes $4.8 billion Amicus Therapeutics acquisition at $14.50 per share

Neutral Impact 4 of 5 m&a Written later

BioMarin completed its all-cash acquisition of Amicus Therapeutics on April 27, 2026, at $14.50 per share, for a total equity value of approximately $4.8 billion. The company funded the deal with $2.0 billion and $800 million term loans under a new credit agreement, plus proceeds from previously issued 5.500% senior notes due 2034 and cash on hand, and it expects to provide updated FY 2026 guidance on May 4, 2026.

Key points

  • Amicus shareholders receive $14.50 per share in cash, and Amicus equity awards were cashed out or cancelled at the same price.
  • New credit agreement with Citibank, N.A. as administrative agent includes a $2.0 billion Term Loan B, an $800.0 million Term Loan A and a $600.0 million revolver, with the revolver undrawn at closing.
  • Term Loan B matures on the seventh anniversary of closing; Term Loan A and the revolver mature on the fifth anniversary.
  • BioMarin expects to provide updated FY 2026 guidance during its first quarter earnings call on May 4, 2026.

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECApr 27, 2026, 8:45 AM ET
Accession number0001193125-26-179243

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.